SLRX Stock Risk & Deep Value Analysis

SLRX

Healthcare • Biotechnology

DVR Score

0.1

out of 10

Distressed

The Bottom Line on SLRX

We analyzed SLRX using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran SLRX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Mar 20, 2026•Run Fresh Analysis →

SLRX Stock Risk Analysis

Overall Risk

N/A (Investment in SLRX as an independent entity is not possible.)

Financial Risk

N/A (Company is delisted)

Market Risk

N/A (Company is delisted)

About SLRX (SLRX)

Sector

Healthcare

Industry

Biotechnology

Market Cap Category

small

Market Cap

$3.85M

SLRX Deep Value Analysis

SLRX (Salarius Pharmaceuticals, Inc.) was acquired by VolitionRx Limited (VNRX) on October 18, 2023, and subsequently delisted. As of 2026-03-20, it does not exist as an independent publicly traded entity. Therefore, evaluating its 10x growth potential within the next 3-5 years as a standalone investment is impossible, making its investment viability for such returns effectively zero. The quoted current price of $7.62 for SLRX is an anomaly for a delisted ticker and does not reflect a liquid, investable asset with growth prospects. No material changes have occurred since the last analysis that would reactivate SLRX as an independent entity, justifying the consistent low score.

SLRX Red Flags & Warning Signs

  • âš 

    N/A (No independent risk events for a delisted company.)

Unlock SLRX Red Flags & Risk Warnings

Create a free account to see the full analysis

SLRX Financial Health Metrics

Market Cap

$3.85M

SLRX Competitive Moat Analysis

Sign in to unlock

Moat Rating

None

Moat Trend

N/A

Moat Sources

1 Identified

N/A (Not applicable for a delisted company.)

N/A (No independent operations to build or maintain a moat.)

SLRX Competitive Moat Analysis

Sign up to see competitive advantages

SLRX Catalysts & Growth Drivers

Near-Term (0-6 months)

  • •N/A (SLRX no longer exists as an independent company; no independent catalysts.)

Medium-Term (6-18 months)

  • •N/A

Long-Term (18+ months)

  • •N/A

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

SLRX Bull Case: What Could Go Right

  • ✓

    N/A (No independent signals to monitor for SLRX.)

Bull Case Analysis

See what could go right with Premium

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.

More Resources to Boost Your Portfolio

Explore our other guides and tools to maximize your investment returns

5-Minute Guide Thumbnail

6 Simple Steps Spotting Undervalued Stocks

Learn More
Dividend Stocks Thumbnail

Earn $500/Month with Dividend Stocks

Learn More
Swing Trading Guide Thumbnail

3 Swing Trading Strategies for Predictable Gains

Learn More